Global Endocrine Testing Market Size By Type (Tandem Mass Spectrometry, Immunoassay), By Application (Hospitals, Commercial Laboratories), By Region, And Segment Forecasts, 2023 to 2032

lobal Endocrine Testing Market Report Description

The Global Endocrine Testing Market was valued at USD 11.3 billion in 2023 and is projected to reach USD 18.6 billion by 2031, growing at a CAGR of 6.7% during the forecast period (2023-2031). The market growth is driven by the rising prevalence of endocrine disorders such as diabetes, thyroid dysfunction, adrenal insufficiency, and osteoporosis. Increasing awareness about hormone-related disorders, technological advancements in diagnostic tools, and the growing demand for point-of-care (POC) endocrine testing are further accelerating market expansion.

Endocrine testing is essential for early detection, accurate diagnosis, and monitoring of hormone imbalances, enabling timely intervention and improved patient outcomes. The integration of advanced technologies like chemiluminescence immunoassays, tandem mass spectrometry, and biosensors is significantly enhancing the accuracy and speed of testing, further boosting adoption globally.

Drivers

Rising Prevalence of Hormonal Disorders

The increasing incidence of thyroid disorders, diabetes mellitus, reproductive health issues, and adrenal gland disorders is significantly driving the need for endocrine testing.

Technological Advancements in Diagnostic Tools

Advancements such as fully automated analyzers, mass spectrometry, and immunoassay technologies are improving the sensitivity and specificity of hormone detection, driving their adoption in hospitals and clinical laboratories.

Growing Demand for Point-of-Care Testing (POCT)

Rapid endocrine tests for thyroid-stimulating hormone (TSH), cortisol, and reproductive hormones are gaining popularity due to their convenience and ability to deliver faster diagnostic results.

Aging Population & Lifestyle Changes

The aging population is more susceptible to endocrine disorders like osteoporosis and diabetes, further driving market demand.

Restraints

High Cost of Advanced Endocrine Testing Devices

Advanced diagnostic analyzers and reagents are expensive, limiting their accessibility in low-resource settings.

Lack of Skilled Laboratory Professionals

The shortage of trained personnel for advanced endocrine testing methods can hinder market growth in developing regions.

Stringent Regulatory Framework

Compliance with strict regulatory approvals for diagnostic devices may slow the introduction of innovative testing technologies.

Opportunities

Expansion in Emerging Markets

Rapidly improving healthcare infrastructure in Asia-Pacific and Latin America creates lucrative opportunities for market players.

Integration of Artificial Intelligence (AI) and Big Data

AI-enabled endocrine diagnostic solutions are emerging as a transformative technology for personalized treatment planning.

Development of Home-Based Testing Kits

Increasing consumer preference for self-monitoring and home-based testing will further drive demand for easy-to-use endocrine testing kits.

Market by Test Type Insights

Based on test type, the thyroid function test segment accounted for the largest market share in 2023 due to the widespread prevalence of thyroid disorders globally. However, the diabetes testing segment is expected to witness the highest growth rate, fueled by the growing incidence of diabetes and the rising adoption of continuous glucose monitoring systems.

Market by End-use Insights

In terms of end-use, hospitals & clinical laboratories dominated the market with over 45% revenue share in 2023, driven by the availability of advanced endocrine testing platforms and highly skilled healthcare professionals. Point-of-care testing centers and home-care settings are expected to see rapid growth due to the increasing demand for decentralized and patient-centric diagnostic solutions.

Market by Regional Insights

North America led the global endocrine testing market in 2023, supported by a strong healthcare infrastructure, high awareness about hormonal disorders, and the presence of major diagnostic companies.

Europe holds a substantial market share driven by increasing geriatric populations and government-supported screening programs.

Asia-Pacific is projected to experience the highest growth rate during the forecast period, driven by rising healthcare investments, growing awareness, and a surge in diabetes and thyroid-related conditions in countries like China and India.

Competitive Scenario

Key players operating in the global endocrine testing market include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Beckman Coulter Inc., Thermo Fisher Scientific, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Quest Diagnostics, Merck KGaA, and Mindray Medical International Limited.

These companies focus on strategic partnerships, new product launches, and technological advancements to expand their market presence. For example:

In 2023, Roche Diagnostics launched an advanced chemiluminescent immunoassay for enhanced thyroid testing accuracy.

Abbott introduced a new POCT endocrine testing device integrated with AI analytics in 2024.

Siemens Healthineers expanded its endocrinology portfolio in 2025 by acquiring a diagnostic start-up specializing in hormone testing biosensors.

Scope of Work – Global Endocrine Testing Market

Key Market Developments

July 2023: Roche Diagnostics introduced a next-generation thyroid hormone test with enhanced sensitivity and faster turnaround times.

March 2024: Abbott Laboratories partnered with leading hospitals in North America to implement its AI-powered point-of-care endocrine testing devices.

January 2025: Siemens Healthineers acquired an innovative endocrine diagnostic company specializing in home-based testing kits, expanding its consumer health segment.

FAQs

What is the current market size of the Global Endocrine Testing Market?

The market was valued at USD 11.3 billion in 2023.

What is the major growth driver of the Global Endocrine Testing Market?

The rising prevalence of hormonal disorders such as diabetes and thyroid dysfunction is the primary growth driver.

Which is the largest region during the forecast period in the Global Endocrine Testing Market?

North America holds the largest market share due to advanced healthcare infrastructure and higher diagnostic awareness.

Which segment accounted for the largest market share in the Global Endocrine Testing Market?

Thyroid function tests accounted for the largest share in 2023, driven by the high prevalence of thyroid-related disorders.

Who are the key market players in the Global Endocrine Testing Market?

Major players include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Beckman Coulter Inc., and Thermo Fisher Scientific.

Would you like me to also create a visually engaging infographic summary of this report for quick reference?